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Abstract  
Smoking is a preventable risk factor for the development of chronic diseases in the lungs, brain, 
heart and kidneys, but smoking can also affect vascular and muscle function. It has been observed, 
for instance, that the smokers suffer from an earlier onset skeletal muscle fatigue that may at least 
partly be caused by toxins, such as carbon monoxide (CO), in the blood. The impact of smoking 
and smoking cessation on skeletal muscle and vascular function however are unknown.  
Methodology. After obtaining ethical approval and informed written consent, we investigated the 
impact of smoking and 2 weeks smoking cessation on muscle and arterial function in 13 participants 
(8 smokers (S); 5 controls (C)). We measured blood CO with a smokelyser and nicotine using an 
ELISA. In the right femoral artery (FA) we measured flow and vasodilation  induced by contractile 
activity and a short occlusion with 2D US. The muscle strength, fatigability of the right Vastus 
lateralis muscle were determined with a dynamometer. Results. The  blood CO (S: 4 ± 0.9%; C: 
0.0 ± 0.0 %,  P < 0.003) and cotinine levels (179 ± 24 vs 27 ± 16 ng·ml-1, P < 0.001) were 
significantly higher, whereas maximal  torque (208 ± 21 vs 259 ± 14 Nm, P < 0.03),  flow (548 ± 
42 vs 714 ± 80 ml·min-¹ P < 0.01) and  FA diameter  (6.8 ± 0.3 vs 7.6 ± 0.2 mm, P < 0.01) were 
significantly lower in smokers than non-smokers. After 2 weeks of smoking cessation, CO 
decreased to 0.3 ± 0.2% (P < 0.01) and cotinine to 30 ± 13 ng·ml-1 (P < 0.02) while there were no 
significant changes in FA diameter, flow, maximal torque or fatigue resistance.    
Conclusion   Our data suggests that the reduced muscle and arterial function in smokers does not 
revert to normal after a short cessation period,  although CO/Cotinine levels decline and may require 
a longer cessation period, supplemented with  antioxidants to stabilize, improve or recover function.  
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Abbreviations  
ATP =Adenosine triphosphate  
C = Non-smokers  
CFA = Common femoral artery  
CO = Carbon monoxide  
COHb = Carboxyhaemoglobin  
COPD = Chronic obstructive pulmonary 
disease  
CVD = Cardiovascular disease 
ED = Endothelial function  
ELISA = Enzyme-linked immunosorbent 
assay  
FI = Fatigue index  
FMD = Flow mediated dilation 
FT = Fatigue test 
HRP = Horseradish peroxidase 
colorimetric conjugate (protein) used  
IMT = Intima media thickness LA = 
Linear array  
 
LFA = Left femoral artery 
MFT = Muscle function test 
MVC = Maximum voluntary contraction 
NRT = Nicotine replacement therapy  
OFR = Oxygen free radicals  
PES = Percutaneous electrical 
stimulations  
QF = Quadriceps Femoris  
RFA = Right femoral artery  
S = smokers while smoking 
SC = Smokers on cessation 
TQ = Torque 
USG = Ultrasonography  
VA =Voluntary activation 
VFT = Vascular function test  
VL= Vastus lateralis  
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1. Introduction and literature review  
Tobacco use is a devastating public health problem. According to World Health Organisation, 1 
billion men and 250 million women worldwide smoke cigarettes daily. Smoking is the single most 
preventable cause of disease and accounts for 5 million deaths per year globally. The top three 
smoking-related killer diseases are cardiovascular disease, lung cancer and chronic obstructive 
pulmonary disease. Although a few approved pharmacological therapies of smoking cessation have 
claimed to be successful, the majority of smokers struggle to quit smoking (Siu, 2010). 
Cigarette smoking is often associated with low levels of physical activity and poor nutrition  
(Mesquita et al., 2015). A growing body of evidence suggests that smoking reduces exercise 
tolerance and increases muscle fatigability (Prior et al, 2004; Larsson et al, 1988; Wüst et al, 2008). 
An impaired lung function and oxygen delivery to the muscle are distinct consequences of smoking 
and may contribute to the increased fatigability of the muscles of the smokers, but also muscle 
atrophy and a slow-to-fast fibre type transition during smoking may impair muscle fatigue 
resistance and exercise tolerance (Wüst and Degens, 2007). Before discussing smoking-induced 
muscle dysfunction, it is important to understand the basic muscle and arterial structure and 
function.(see appendix 1 ). This will be followed by a literature review of the effects of smoking on 
vascular (section 1.1) and muscle (section 1.2) function.  
1.1 Smoking and vessel function 
1.1.1 Common Femoral Artery (CFA) Diameter in health  
 
The vastus lateralis muscle is considered as the largest part of the quadriceps femoris muscle in the 
thigh. It is supplied by the common femoral artery and its branches. There are very few studies 
related to the CFA size and diameter in normal subjects and even fewer that compare the effect of 
smoking or smoking cessation on CFA in relation to the contractile activity of the muscle. However, 
a preliminary study has shown that CFA diameter decreases with age, which may be a consequence 
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of reduced sensitivity to and or impaired release of nitric oxide (NO) by the endothelium (Trinity 
et al, 2012)   
Dysregulation in the balance of endothelium-secreted vasodilators and vasoconstrictors can be a 
result of endothelial dysfunction (ED), characterized by a 
compromised dilation of the vessel in response to vasoactive 
substances such as NO, but also other vasodilators such as 
endothelium-derived hyperpolarizing factor (EDHF). ED is 
commonly present in individuals with chronic diseases such as 
atherosclerosis, hypertension, type II diabetes, and in smokers 
(Barton, 2011). Fig (Left) Cross-section of a normal artery and 
damaged by J Norah  yoursurgery.com 
 
 
1.1.2. Vascular supply to the skeletal muscle fascicle  
Apart from increasing the blood viscosity, plasminogen, platelet and fibrinogen levels in the blood, 
cigarette smoke reduces the capacity of blood to deliver oxygen to the muscle cells and cause 
atherosclerosis   (Celermajer,1993; Ambrose and Barua, 2004). The NO-dependent endothelial 
function test, called flow mediated dilation (FMD), was devised by Celermajer 20 years ago  
(Celermajer, 1993) and  may show differences depending on the artery tested, placement of the 
occlusion cuff and duration of cuff occlusion (Trinity, 2012). 
The skeletal muscle function depends on oxygen and nutrients for its contraction and the blood flow 
to the muscle is thus critical for the overall muscle performance (Prior et al., 2004). This is evident 
by the increase in the capillary-to-fibre ratio, the diameter of the vessels and flow capacity in the 
capillary bed of regularly exercised muscles. Further, the capillary bed that supplies a particular 
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muscle group might increase in the number of capillaries (angiogenesis) to match the energy 
requirements of that muscle (Prior et al., 2004). Likewise, because of disuse, the loss of muscle 
mass may be accompanied with a reduction in the number of capillaries to that muscle (Degens & 
Alway, 2006). 
Pitcher & Miles (1997) examined the influence and mechanism of increased muscle blood flow on 
the prevention of muscle fatigue during isometric exercises of the hand muscles. Others found and 
suggested that the occlusive reduction of blood flow, low oxygen levels and formation of 
inflammatory free radicals may contribute to the diminished muscle endurance in smokers (Degens 
et al, 2015). Another study  reported that the blood flow modulation mechanism to the muscle, was 
located in the vessel wall  and that it facilitated  the  insulin-mediated glucose uptake by muscle 
fibres, which  was dependent on capillary recruitment (Clark et al., 2003). 
It is well established that type I fibres have a significantly higher oxidative capacity than type II 
fibres. In this regard, Laughlin and Armstrong (1982) noted that the blood flow to type I fatigue 
resistant fibres during a constant and graded exercise was four times more than that to type II fibres. 
Further evidence for the importance of blood flow for fatigue resistance comes from the observation 
that muscle fatigue is increased dramatically after abolishing flow to the muscle (Wust et al., 2008) 
and the fact that increasing perfusion pressure increases muscle fatigue resistance (Petrofsky & 
Hendershot, 1984). 
1.1.3 Effects of smoking on vascular function  
 
Blood flow to the muscle can be increased by vasodilation. Vascular diameter and vascular tone is 
the result of a fine balance between vasoconstriction and vasodilation. Endothelial cells have surface 
receptors that can sense stress-mechanic forces by sending out vasodilator signals for relaxation. 
Endothelial cells also respond with NO release to various stimuli like ADP, bradykinin, and 
calcium. Smoking related structural and mechanical damage to the endothelium, by substances in 
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smoke, such as carbon monoxide, nicotine and cotinine, can interfere also with the acetylcholine-
induced vascular dilation (Mayhan, 1998; William, 1999; Hosokawa, 2008;Mayhan and Sharpe, 
1998, 1999; Hosokawa et al., 2008). The core feature of ED commonly seen in chronic smokers is 
indeed  impaired bioavailability of NO and altered response to ACh, which reflects  as  a disease 
state, with increased vascular rigidity and flow disturbances (Celermajer et al., 1993; Hosokawa et 
al., 2008). Smoking has also been reported to affect the microcirculatory network of tissues, causing 
permanent distal tissue damage that was attributed to drop in oxygen tension and increased lactate 
accumulation (Lehr,2000; Luu,2013).  The observed degenerative necrosis of cells was attributed 
to nicotine and proportional to the dose and duration of exposure and reductions in tissue blood 
flow (Lehr, 2000). Others, however, observed that nicotine caused “narrowing and widening” of 
the red cell column, as in  the healthy and stated that  if there was a drop in capillary blood 
flow/decline in smokers, it was not related  to the  nicotine content or level  in cigarette 
(Richardson,1987).  
Any alterations to normal arterial diameter parameters per se may have functional consequences in 
tissue function (Pohl, 1986). In a study of brachial artery endothelium already as smoking as little 
as one  cigarette diminished effective  arterial vasomotion for 60-90 minutes, while repeated smoke 
exposure reduced  lumen and  the tissue blood flow  and may over time precipitate cardiovascular 
events such as stroke or heart attack (Lekakis et al., 1998).  
The lowered flow (51%) in chronic smokers was  associated with  lowered  muscle glucose uptake 
and metabolism, which could be overcome by insulin infusion (Ronnemaa et al., 1999).   This 
suggests that lowered blood flow in smokers was also directly and simultaneously linked to the 
lowered muscle glucose uptake in muscle that could contribute to an early muscle fatigue 
(Ronnemaa, 1998). Thus, firstly it is suggesting that the overall flow reduction to the muscle and 
the associated reduction in glucose uptake is reversible and suggests that also muscle fatigability in 
smokers is readily reversible by smoking cessation.. 
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1.1.4. The effects of smoking cessation on vessel function.  
Even a low dose of smoke exposure, such as that experienced during passive smoking,  impairs 
endothelial function in healthy young children (Kallio et al., 2009). Another study concluded that 
the nicotine and CO levels, apart from increasing the blood viscosity and propensity to blood 
clotting, could also greatly decrease micro perfusion and tissue oxygenation (Lee et al., 2013).  In 
smokers, the L arginine-NO pathway was impaired and resulted in a reduced NO production (Takajo 
et al, 2001). These changes were exclusively attributable to the higher nicotine dose exposure, in 
heavy smokers and were reversed after two weeks of smoking cessation (Morita et al., 2006). 
Further, the platelet aggregation was later enhanced again by re-initiation of regular smoking. This 
suggests that smoking-induced cellular platelet aggregation; vessel dilation and flow malfunction 
was associated, partly with the blood nicotine levels and oxidative stress. Further, oxidative stress 
and muscle endurance could be restored and enhanced by high dose of antioxidants, suggesting a 
vital role  for antioxidants in the muscle fatigue reversal process (Kallio, 2007; Meyer et al., 2013).  
 
         1.1.4.1. Smoking Cessation  
Nicotine is a major active component in tobacco smoke. It is not considered a pathological agent, 
although its presence in blood induces some inflammatory responses due to its metabolite 
constituents. However, upon smoking cessation, the abundance of foreign particles that cause 
inflammation and oxidative stress, and the presence of nicotine metabolites and carbon monoxide 
quickly return to undetectable levels in the blood. Given these observations, parallel reductions in 
oxidative stress and recovery of tissue function are to be expected to follow smoking cessation. In 
line with this, the negative effects of smoking on platelets were reversed after two weeks of 
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cessation. Additionally, Endothelial Dysfunction was reversible in just 24 hours of smoking 
cessation (Morita et al., 2006).  
 
 1.1.4.2. Effect on Mitochondrial dysfunction  
Smoking-related mitochondrial dysfunction, reducing aerobic ATP production, has been suggested 
to underlie the increased fatigue and muscle dysfunction (Degens et al., 2015). Mitochondrial 
dysfunction has been seen in many muscle diseases.  The increased circulating levels of CO from 
the inhaled smoke causes COHb formation and consequently a decline in tissue oxygenation (Lee 
et al., 2013). CO can also bind to components of the respiratory chain and has indeed been shown 
to reduce by 23% the mitochondrial respiratory chain /complex IV activity [cytc-ox activity] 
(Alonso et al, 2003).  At cellular level in the skeletal muscles from smokers, reduced mitochondrial 
density, impaired mitochondrial respiratory chain complexes reaction and coupling are reported. 
These changes may well be reversible by smoking cessation (Meyer et al., 2013). 
 
  1.1.4.3. Voluntary activation of muscle  
To produce maximum voluntary isometric contraction of muscle, concentration and effort is 
required to fully activate the muscle. It is possible that the activation of the muscle is impaired in 
smokers, but there is also a possibility that it is increased as increased levels of nicotine in blood 
stimulates acetylcholine receptors. 
 
1.1.5.  Biomarkers of smoking in blood:  
1.1.5.1.Carbon monoxide-related hypoxia 
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Carbon monoxide (CO) formed from partial combustion of hydrocarbons in the cigarette smoke 
hinders oxygen delivery and its utilisation by mitochondria for aerobic ATP production. Part of the 
problem is related to the binding of CO to haemoglobin, forming carboxyhaemoglobin (COHb), 
thereby reducing the oxygen carrying capacity of the blood by up to 15% available oxygen from 
RBCs.  Marketed as “safe” and “Organic” cigarettes produce 75 times more CO than traditional 
cigarettes, potentially even further reducing tissue oxygenation. Its rapid binding to Hb is 250 times 
stronger than oxygen, so that the smoke -inhaled CO in effect competitively displaces oxygen from 
Hb. The combination of CO with Hb also shifts the O2 dissociation curve of the HbO2 to the left, 
making the release of the bound oxygen more difficult and thereby adding to the hypoxic state of 
the tissue of smokers.  
Given the above considerations CO can be thought off as a poisonous gas, due hindering the 
transport of oxygen to tissue by binding not only to Hb, but also myoglobin, and its inhibition of 
complex IV in the mitochondria (Gonzalez-Alonso, 2003; Gorman et al., 2003; Prockop and 
Chichkova, 2007). While many studies support the traditional CO “hypoxic” cytotoxicity theory 
others suggest rapidly progressive Nitrative stress as a consequence of CO-related cell death  (Thom 
et al., 1997, 2000; Patel et al., 2012) . 
  
 1.1.5.2. Nicotine  
Biomarkers of smoking in blood may be indicative for the degree of smoke exposure of an 
individual. Twenty-one metabolites are elevated in serum of smokers and thus can act as potential 
biomarkers of smoking status. Smoking cessation both reduced these levels and the associated 
disease risk (Xu et al., 2015). One such marker is the breakdown product of nicotine: cotinine 
(Neunteuft et al, 2002). Direct effects of nicotine have been documented.  
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Long term, intense, repeated nicotine exposure induces desquamation damages, physically destroys 
endothelium and causes “junctional leaky holes” in the basal membrane that accelerates 
atherosclerosis (Villablanca, 1998; Lin et al, 1992; Lehr, 2000). This endothelial cell injury and loss 
of endothelium, increases selective permeability of the endothelium, and transport of 
macromolecules like LDL to and through the intercellular clefts, that is further accelerated by 
smoking-induced inflammation (.Lin et al, 1992). Apart from endothelial dysfunction and changes 
in endothelial structure, nicotine also  selectively enhances noradrenalin-mediated constriction of 
deep arteries in bones that  in effect  results in chronic reduction in bone blood flow and function 
(Feitelson et al, 2002) and may underlie the reduced bone strength in smokers (Wust et al., 2010).  
It has been demonstrated that smokers have a decreased blood supply in conduit arteries (Celermajer 
et al., 2003) and suffer greater peripheral muscle fatigue than non-smokers (Wust et al., 2008). The 
decreased blood supply is considered as the main reason for this. 
 
 
1.2. Smoking  
1.2.1. Muscular effects  
Smoking and muscle strength and mass 
 
Smoking is also associated with a lower lean body mass that is associated with the lower muscle 
force (van den Borst et al., 2011). Smokers also have a reduced capillary to fibre ratio (Montes de 
Oca et al., 2008; Wust et al., 2008a). This lower capillary supply can result in reduced tissue 
oxygenation and contribute to the early muscle fatigue in smokers. Given these findings, it is likely 
that continued smoking causes progresses muscle dysfunction. Muscle wasting and weakness in 
smoking maybe reversible by smoking cessation 
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Some studies have reported that skeletal muscles of smokers have lower muscle force than healthy 
non-smokers, but it is not clear whether this weakness is due to smoking per se or due to inactivity 
in smokers. The consensus is, however, that smoking per se can induce muscle weakness (Barreiro 
et al., 2010; Saito, 2012; Degens et al, 2015).   Part of the weakness is attributable to a lower muscle 
mass, that may be associated with up to 25% fibre atrophy (Montes de Orca et al., 2008). This 
supports the idea that smoking can cause muscle atrophy and subsequent weakness 
 
1.2.2. Muscle damage   and fatigue 
Muscle Fatigue that is being suspected  to occur in smoking is weakness, and is generally defined 
in terms of the loss of ability to generate force (Jones & Round, 1990).  During exercise, fatigue 
develops where the individual is no longer able to perform exercise at a required level. Part of this 
inability to perform the exercise is thought to be due to the muscle fatigue, which may be caused 
by a progressive rise of cellular metabolites viz., H+, Pi, lactate, and pH decline because of 
glycolysis, within the locomotor muscles (Jones and Round, 1990). 
 
Acrolein and acetaldehyde in cigarette smoke have been shown to induce muscle protein breakdown 
(Rom et al, 2013). In addition, cigarette smoke has high-level pro-oxidants, such as reactive nitrogen 
species, (RNS) that induce Nitrative and nitrosamine stress. Peroxynitrite in particular was involved 
in p38 MAPK phosphorylation during oxidative stress and caused down regulation of myosin heavy 
chain protein expression (Rom et al, 2012, Takajo et al., 2001).  Smoking of even one cigarette can 
raise blood acetaldehyde level by 9.4 µM and sustained elevated levels in smokers may contribute 
to the decline in muscle function observed in smokers.  Similar to acetaldehyde, 25 µM acrolein 
exposure of C2 myotubes induced rapid wasting and loss of myosin (REF). While other substances 
in smoke may also cause injury acrolein specifically is highly toxic to muscle and is 10 times more 
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abundant in saliva and breath of smokers than non-smokers and supports the notion that acrolein 
may cause muscle breakdown and muscle weakness in smokers (Rom et al., 2013). 
 
Muscle weakness in smokers may also be related to decline in blood flow Each inhaled smoke puff 
has nicotine, CO, CN and about 1015 free radicals and it is therefore no surprise that oxidative stress 
is common in smokers, that in turn leads to systemic inflammation. To make matters worse, 
systemic inflammation induces further production of Reactive oxygen species (ROS), Reactive 
Nitrogen Species (RNS), superoxide anions, which activate breakdown of proteins. It is thought 
that systemic inflammation and oxidative stress are two factors that contribute to the muscle protein 
breakdown and weakness in smokers (Takajo et al, 2001; Rom et al, 2013). It is interesting to note 
that mice exposed to cigarette smoke had a lower VL muscle mass that was strongly associated with 
the reduced force generation, which occurred by a parallel 51% decrease in femoral arterial flow 
(Montes de Oca et al., 2008; Ronnemaa, 1998). 
1.2.3.  Muscle fatigue resistance in smokers 
Studies conducted by our group have previously shown that smoking causes a reduction in the 
skeletal muscle fatigue resistance independent of smoking history and physical activity level (Wust 
et al. 2008). This occurred in the absence of significant changes in muscle fibre type composition, 
fibre size, capillarisation and the activity of succinate dehydrogenase (SDH). It is not clear whether 
the reduced fatigue resistance is due to impaired oxygen delivery to muscles and/or due to damaged 
blood supply within the muscles. When matching age and activity, some studies have shown that 
muscle fatigability was associated with decline in aerobic metabolism in smokers (Barreiro et al., 
2010; Degens et al, 2015). 
It has been shown that CO inhalation that resulted in 6% carboxyhaemoglobin, as commonly 
observed in smokers, leads to similar reductions in muscle fatigue resistance (Morse et al., 2007) as 
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that observed in smokers, suggesting that fatigue in smokers was related to  decreased oxygen 
supply to the muscle (Celermajer et al., 19943?; Moreno et al., 1998). Indeed, an adequate blood 
flow is a critical factor for muscle performance and smoking has been shown to diminish peripheral 
blood flow and sheer stress of the femoral artery in humans (Ronnemaa, 1998). To a certain degree, 
these factors were reversible by regular exercise (Anton et al., 2006) and smoking cessation for 8 
weeks has been shown to restore venular and arteriolar function and endurance (Hashizume et al., 
2000; Morita, 2006).  
In exercising muscles the red type I fatigue resistant muscle fibres receive 4 times more blood flow 
than fatigue prone type II muscle fibres (Laughlin & Armstrong, 1982). This suggests that the high 
aerobic ATP production in type I fibres requires a constant oxygen supply, derived from the 
relatively large blood flow. This blood ultimately comes from the arteries and one could thus 
hypothesize that a decreased blood flow in smokers is one of the factors cause their reduced skeletal 
muscle fatigue resistance. Indeed, restriction of blood flow reduced fatigue resistance in hand 
muscles during isometric exercise performance significantly, independent of the aerobic capacity 
(Pitcher and Miles, 1997; Samra and Levine, 2015). Thus, decreased oxygen transport causing an 
impaired aerobic ATP generation and cardiovascular capacity was responsible for the accelerated 
onset of muscle fatigue during hypoxia. This indicates that as long as blood flow remained reduced 
or restricted, muscle endurance was impaired. Such a mechanism may be at work in smoker. 
 
 
1.2.4 Oxygen supply and muscle function   
 Relatively less oxygen and more free radicals create an inflammatory response that may impair 
fibre performance (Degens et al, 2015). Some molecules in smoke could also damage muscle 
proteins and hinder protein synthesis, which could result in muscle weakness, while vascular 
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impairment  may contribute to the earlier onset of muscle fatigue in smokers (Wust et al , 2008). 
Increased in vascular resistance, reduction in flow and hypoxia, commonly seen in smokers, appears 
to be dose related  (Ronnemaa, 1998; Lehr, 2000; Celermajer, 1993) 
 
  1.2.4.1. Muscle loss and oxidative stress- pathways  
 The whole vapour phase of cigarette smoke promotes muscle catabolism, increases protein 
breakdown and reduces protein synthesis. The vapour phase of smoke, primarily with 1015 free 
radicals per puff, has CO, aldehydes and nitrogen oxides (Fielding, 2012) these substances induce 
intracellular inflammation and increased oxidative stress via oxygen free radicals and reactive 
nitrogen species stimulus. There are many cellular model pathways that when activated by 
inflammation affect muscle proteins. These include: 
Nuclear Factor-kB (NF-kB) signalling pathway. The function of this pathway is to modulate 
inflammation and immune responses. In atrophic models, it has been shown that activation of this 
major pathway induces rapid degeneration of muscle and initiates myofibril death while its 
inhibition prevents atrophy. The aldehydes in the gas phase of cigarette smoke are volatile, toxic 
and soluble products that are carried by blood directly to muscle cells. C2C12 myotubes are directly 
affected by the vapour phase of tobacco smoke and show a reduced diameter and mass in proportion 
to smoke dose and exposure duration (Caron et al., 2013). Saturated acetaldehyde and unsaturated 
aldehyde acrolein in smoke is thought to be responsible for the direct structural and metabolic 
muscle breakdown. Pro-inflammatory cytokines disturb muscle energy pathways and stimulate the 
ubiquitin-proteasome system (Davidsen et al, 2014; Degens et al, 2015). 
p38 MAPK is another pathway involved as a first step in muscle fibre loss is p38 MAPK activation. 
The P38 MAPK signalling pathway is activated by oxygen free radicals, such as those in cigarette 
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smoke, and stimulates in turn the muscle specific E3 ubiquitin ligases/- proteasome system that 
breaks protein resulting in the rapid muscle atrophy.  
These pathways may thus underlie the decline in contractile function and the earlier onset of muscle 
fatigue in smokers.  
 
 1.2.4.2.   Mechanism of oxidative stress [Oxidative Stress]  
Smoking causes oxidative stress that increases with smoking intensity.  This oxidative stress may 
underlie the endothelial dysfunction and impaired blood flow during exercise (Tanriverdi et al, 
2006). People who quit smoking exhibit less oxidative stress due to increased antioxidant defence 
gained during the period of smoking.   Thus, a major benefit of smoking cessation is to reduce 
oxidative stress (Lane et al., 1997).   
 
1.2.5.  Smoking Cessation  
It is speculated here that smoking cessation would reverse many of the adverse effect of smoking 
on both skeletal muscle as well as vascular function. Some past cessation studies as mentioned 
below, have indeed reported an improved muscle force but it was not clear whether this 
improvement was  clearly due to cessation alone or due to some other cardio-vascular factor in 
smokers, as also arterial function improved (Green et al., 2012; Caron et al., 2013).  
A factor that might contribute to such an improvement is the potential reversal of systemic 
inflammation and oxidative stress (Rom et al, 2012). Furthermore, cessation increasing antioxidant 
and DNA reparative mechanism in tissue (Lane, 1997; Ishida, 2014). Other studies have suggested 
that muscle improvement after smoking cessation was linked to arterial remodelling and cardiac 
muscle adaptations (Benowitz, 2013). 
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 1.3.  Aims and objectives of the project  
Considering that substances in cigarette smoke, such as nicotine, carbon monoxide (CO), cyanide 
(HCN), aldehyde and others may interfere with the delivery of, and ability to use, oxygen by the 
muscle, the aim of this study was to understand to which extent smoking cessation can reverse some 
of the detrimental effects of smoking on vascular and muscle function.  
 
1.3.1. Objectives 
1. To review the literature on the effects of smoking and smoking cessation on muscle and 
vascular function  
2. To determine the levels of indicators of smoking habits in the blood 
3. To assess  muscle function before and after smoking cessation 
4. To assess  vascular  function with Doppler ultrasound before and after smoking cessation 
 
2.6 Hypothesis  
Smoking results in reduced skeletal muscle fatigue resistance that is related to impaired vascular 
function. This cumulative smoking-induced impairment of the muscle and vascular function is 
reversible by two weeks of smoking cessation. 
Our pilot study research will focus primarily on the muscle function (strength and fatigability) in 
relation to endothelial function in chronic smokers and after 2 weeks of smoking cessation.  
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3. Methodology 
3.2 Recruitment and selection  
Male and female smokers and non-smokers: (17 Participants in total) were invited by email, poster 
advertisement and in person to participate the smoking cessation study. Participant characteristics 
are given in table 1 .The advertisement flier briefly described the purpose and expected outcome of 
the research study (see appendix 2 for poster advert). 
   
Inclusion criteria 
Participants above 18 years of age and healthy as judged by their medical history and self-reported 
questionnaire and physical demography, were included in the study. The basic condition was that 
the smokers regularly smoked at least five cigarettes per day for at least three months preceding the 
study. Participants were familiarised with the laboratory set up.  A written consent was obtained 
after the purpose, nature and outcome of the study and possible risks and hazards were explained to 
the participants. (See appendix 5 for consent form and description). The experimental protocols 
were approved by the Ethics Committee of the Manchester Metropolitan University.  
Exclusion criteria  
1.  To minimize the effect of confounding factors of morbidity and functional outcome participants 
having any muscle, cardiovascular, lung, joint, or metabolic disease or reportedly taking any 
oral, injectable or inhalant medication were not included in the study. Pregnant women and 
people 60 years and older were excluded. In addition, ex-smokers and habitual smokers 
unwilling to refrain from smoking for two weeks were excluded from the study. One participant 
was found using a small dose oral contraceptive pill and another a regular high dose anti-
histamine, both of which could affect blood vessels, and were excluded from participation.  
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2. A final group of 13 fit gender, mixed-race and age-matched participants were recruited; eight 
were smokers (five males, three females) and five were non-smokers (four males, one female).  
 
3.1 Subject preparation  
All subjects arrived at the lab after an overnight fast (of 6-8 hours), specifically with no alcohol, 
caffeine and fatty food intake the night before the lab visits. In the morning, they were allowed to 
consume a light non-fatty breakfast. Smokers were permitted to smoke as usual, such that their last 
cigarette smoked would be the one just before the sample of blood was taken before the 2-week 
abstinence.       
At day 1 (D1) participants were classified as current smokers (S) and non-smokers controls (C). All 
measurements were carried in the environmentally controlled lab premises after allowing about to 
5-20 minutes to reach hemodynamic stability, as verified by a stabilised heart rate (HR).  All the 
muscle function tests (MFTs) were performed in the right Vastus lateralis muscle). On the left side, 
the flow mediated dilation (FMD) of the femoral artery (FA) was carried out with Doppler 
Ultrasonography (USG). 
First, the baseline height and body mass were measured. HR, blood pressure (BP) and COHb were 
measured; then  later with a Smokelyser. A venous blood sample was collected from the antecubital 
vein, 5-10 min after smoking one full cigarette (for smokers), by a certified phlebotomist. The 
samples were mixed, centrifuged at 3000 RPM for 10 min and serum separated and stored at -800 
C for analysis later. The entire measurement procedure took a maximum of two hours, starting with 
a smoking bout, blood collection and muscle, vessel and FMD measurements.  
The test order, for both smokers and non-smokers was as follows:  
1. (Pre) Resting vascular function in the right femoral artery RFA before muscle function – 
in this test the resting vessel Diameter, Velocity and flow were determined (≈10 min) 
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2. Muscle function in the right R Vastus Lateralis (VL) – maximal voluntary contraction 
force (MVC), voluntary activation (VA) and fatigue test (≈1 hour) 
3. (Post MFT) Vascular function immediately after the fatigue test (same as 1) (2-3 min)  
4.  LFA Flow mediated dilation (FMD) (≈duration 8 min) 
To determine whether the decreased arterial blood flow in the smokers was responsible for the 
lowered muscle force (MVC) and fatigability, blood flow at before and after the muscle contraction 
test was performed. To test if short smoking cessation improved vasodilation by improving 
endothelial function, we conducted and FMD Test after 2 weeks of smoking cessation. To test if 
cessation-mediated improvement in smokers had improved both flow and muscle function, we also 
repeated the muscle function tests after 2 weeks of smoking cessation. 
  
All tests were performed in the same sequence as described above before and after 2 weeks of 
smoking cessation. Vascular function before and after the fatigue test was determined in the R FA 
using a high-resolution ultrasound probe, in which the FA diameter (mm), blood velocity (cm/s) 
and blood flow (ml/min) were measured. The four muscle functions parameters assessed were 
isometric maximum voluntary contraction (MVC) (N), Torque (N.m), Voluntary activation (VA %) 
and the 2-min fatigue test (FT). A custom-made isometric dynamometer (Amsterdam chair, VU 
Amsterdam, the Netherlands) with standardised approved protocols was used. Lastly, an 8-minute 
FMD test was carried out on L FA, to test how vascular endothelial function is affected by smoking 
and smoking cessation. To test the level of smoking and whether smokers really abstained from 
smoking, COHb in the exhaled air, and serum Cotinine in blood  by ELISA assays, was measured.  
Under supervision, our team of three independent investigators assisted in the collection of muscle, 
vascular function and blood data. Each investigator at same time was responsible for one particular 
part of the experiment.   
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3.2 Experimental Tests  
3.3 Biomarkers of smoking (Cotinine and COHb) 
 
As a marker of smoke exposure, we determined the level of blood Cotinine, a metabolite of absorbed 
nicotine, by ELISA assay. On the arrival at the laboratory, on day 1 (D1) of the test, 5-10 minutes 
after smoking their chosen standard size cigarette, a sample of 3-5 mL venous blood was collected 
from antecubital vein in the forearm, in 10 ml sized vacutainer tubes in sterile condition. 
 
Cotinine 
An enzyme linked immunosorbent assay (ELISA) was used to measure cotinine in serum. Standards 
from the National Institute of Standards and Technology were used for comparison. Test serum 
sample of acute smoker and specimen serum sample of non-smoker control were taken. A ready-
to-use cotinine HRP enzyme conjugate was added in duplicate to the selected wells coated with 
anti-cotinine polyclonal antibodies. Cotinine in the collected serum sample competes with a 
cotinine-HRP conjugate for binding sites. Unbound cotinine and cotinine enzyme conjugate was 
washed out by a series of washing steps. Upon the addition of substrate, the intensity of colour was 
inversely related to the concentration of cotinine in the collected samples. The standard curve was 
constructed relating the colour intensity to the concentration of the cotinine. All testing was done at 
room temperature (18-26⁰ C). Using a precision pipette, 10 µL of standard, controls and test 
specimen were pipetted. Further, 100 µL of enzyme conjugate was added to each well. The plate 
was then shaken for 10-30 seconds to ensure proper mixing. It was then incubated for 80 minutes 
at room temperature in the dark. The wells were washed six times with 300 µL-distilled water using 
an automatic plate washer. Care was taken not to cross-contaminate wells. Wells were inverted and 
vigorously slapped dry on the absorbent paper to ensure that all residual moisture was removed. 
This step was critical to ensure that the residual enzyme conjugate did not skew the results. Using 
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an automated system, we ensured that the final aspiration on the wash cycle was aspirated from 
either side of the well. Then 100 µL of substrate reagent was added to each well and incubated for 
30 minutes at room temperature in the dark. Finally, 100 µL of stop solution was added to each well 
and the plate was shaken gently to mix the solution. The absorbance on ELISA reader was read at 
450 nm within 15 minutes after adding the stopping solution. To construct the standard curve, we 
plotted the absorbance for cotinine standards (vertical axis) versus cotinine standards concentration 
(horizontal axis) on a linear graph paper. The best-fit polynomial trend line was drawn through the 
points. Equation and R2 was displayed.  The absorbance for controls and each unknown test sample 
was read from the curve.  
COHb estimation  
 
COHb estimation was carried out using Smokelyser (Micro 4 Smokelyser, Bedfort scientific Ltd. 
Kent, and England). Five minutes after smoking a cigarette, the smoker participant was asked to 
hold the breath and breathe out slowly into the breathalyser, which analysed the CO in the expired 
air and digitally displayed the reading on the screen. The COHb in exhaled breath measure was 
given in %. 
3.4 Cardiovascular function (Heart rate, Blood pressure) 
To determine the effect of smoking on central cardiovascular parameters at rest before and after 
cessation, we measured heart rate, systolic blood pressure and diastolic blood pressure using an 
automated digital sphygmomanometer (Omron). Then cardiovascular parameters were calculated: 
mean arterial pressure, rate pressure product and pulse pressure. Peripheral vascular resistance, 
cardiac output and stroke volume was calculated using standard equations and formulae (see 
appendix). 
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3.4a  Vascular function measurements 
To determine if muscle fatigue was due to flow decline, femoral artery function was determined 
with Doppler-ultrasound with a multi-frequency LA 5-14 MHz transducer (Esaote MyLab-70, 
Netherlands; Figure 3.1). 
  
3.41 Diameter,  velocity and flow  
We measured blood vessel diameter, blood flow velocity and flow in the femoral artery before and 
after smoking cessation with optimal predefined imaging pre-sets and output calculated 
automatically with inbuilt algorithms and installed software. 2D visualisation with B-mode pulsed 
wave US Doppler with spectral analysis, had four major advantages in that it was non-invasive, 
radiation safe and a reliable and validated method for characterizing flow dynamics in the femoral 
artery.  
In the right thigh common femoral arterial segment that lies in the anatomical region of femoral 
point was surface marked at the junction of lateral 2/3rd point between the anterior superior iliac 
spine and the pubic symphysis. Female volunteers were always assisted by a female chaperon to 
access the lower abdominal region at the upper thigh regions. The medial region was covered with 
a towel and the transducer probe was held in place while measurements were made.  
In the resting supine position after hemodynamic stability was achieved, the femoral area of the 
inguinal region, longitudinally the right common femoral artery (CFA) segment 1-2 cm above the 
bifurcation of deep Profunda Femoris artery was assessed for standardisation (Sandgren et al, 1999). 
The small segment, with anterior and posterior vessel wall clarity with luminal surfaces in between, 
was chosen for continuous 2D greyscale imaging. Its cross-sectional area was taken for reference 
to determine the maximum diameter of the lumen, since adequate image definition is also possible 
of its sidewalls. The diameter of the arteries using B mode, was measured with ultrasonic callipers 
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twice in the end-diastole and end-systole. The femoral artery diameter (D), velocity (V) and blood 
flow (VO) were measured in each participant on two occasions.  
To ensure a good imaging contact with the skin and ultrasound transducer, a generous amount of 
ultrasound transmission gel was applied on the probe and securely held on the femoral point of the 
right thigh until steady coloured pulsation were clearly visible. The femoral artery region was 
specifically located on the US screen to visualize the arterial movement cross-sectionally. The good 
quality stable images were then captured in cross-section and longitudinal axis. First, the reference 
FA cross-section image was taken. The probe was later moved in transverse direction to record the 
clear anterior-posterior wall movement at the longitudinal section, two cm above the bifurcation of 
the profunda femoris artery. Using the basic and advanced image optimization techniques for 
ultrasound and with customized vascular pre-sets, the 2D real-time femoral artery images and clips 
were recorded. Automated optimization vascular pre-sets of frequency, depth, resolution and 
insonation angles were consistently used to collect still images and video flow clip data at a 29 
frames/sec rate before and after muscle function tests (MFTs). A live clip over 20-40 beats in a 
steady state was also recorded after mid-arterial sample volume was adjusted to cover the width of 
the entire blood vessel and was taken continuously at a 600-insonation angle. The velocity recording 
sample volume was 2 mm mid-arterial and corrected angle of 600 with cursor parallel to the vessel 
lumen.  The blood flow parameters were measured in supine position and recorded as stable spectral 
trace as Timed Average Velocity, blood flow and blood vessel diameter.  From the recorded images, 
3-4 best recorded vessel segments of the 10 cardiac cycles was chosen for the measurement and 
analysis (Harris et al 2010). The end-diastole in the R wave and the peak T wave end-systolic 
diameter are larger and were used for better assessment of vasodilation effect and diameter changes 
in relation to smoking status. Blood flow parameters were automatically calculated from the best 
quality segment, using the principle of instantaneous mean blood velocity over the cardiac cycle, 
26 
 
using analysis of waveform of the Doppler-shift effect, beat-by-beat flow seen as a time velocity 
integral profiles.  
3.5 Muscle functions  
 Maximum voluntary contraction (MVC)    
To test the maximum ability to generate muscle force of the extensor muscles, the volunteers wore 
lose shorts, comfortable enough to access the upper part of the shaved thigh skin surface over the 
four knee extensors. Two electrodes were placed at the ends of QF. The Participants initially were 
asked to do three small repetitive isometric contractions as a warm-up. Familiarization with machine 
and muscle function recording,  strapping, testing with PES and fatigue testing, USG (before and 
after) test requirement, timing, FMD was  carried out on a separate occasion before the actual data 
collection.  
The Participants were asked to sit on a custom-made Amsterdam chair with their arms across their 
shoulders. The Amsterdam chair is a computer assisted Isokinetic dynamometer setup that tests and 
measures contractile performance of muscles groups (e.g. Knee extensors). It is used here to 
examine strength and fatigability of knee extensors. A shin strap below the knee and an abdominal 
harness above the upper limit of the femoral region was applied to stabilize the upper torso for 
maximal force generation in knee extensors and prevention of extraneous movement. After the 
warm-up session, the lever length was measured from the lower end of the femur lateral condyle to 
the top of the connection with the force transducer. A computer screen showed the muscle force and 
participant were asked to put in maximal effort. While visual feedback of the muscle force was 
provided, an additional verbal motivation was given. To ‘push’ against the shin restraint to extend 
the knee, as strongly as possible, to contract the quadriceps muscle maximally three trial with a 
small rest in between, were performed and the maximal value recorded as MVC in Newtons (N).  
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 Voluntary activation (Interpolated twitch technique) 
Voluntary activation levels were determined using the interpolated twitch technique with a doublet 
pulse. The current used to test the activation was determined using single pulses with the 
participants in a relaxed state, starting from 100 mA, increasing the current until no further increase 
in torque was observed. The first doublet was applied with the participants in a relaxed state, and 
the second one was delivered during the plateau phase off the MVC. The ratio of interpolated and 
resting doublet was used to provide an index of activation as given by the formula: 
Voluntary activation (%) = 100 x (1- (superimposed doublet torque /resting doublet torque),  
where the superimposed doublet torque is the additional torque during the MVC caused by the 
doublet. 
For this stimulation the anode was placed over the proximal skin region of the quadriceps muscle 
and the cathode over the distal tour of the upper leg. Percutaneous electrical stimulation (PES) 
(square wave, pulse width 50 µs, DSV Digimeter stimulator, Digimeter Ltd., Herts, UK) was 
applied using carbon rubber pads (76 mm x 127 mm, Versastim, Conmed Corporation, New York, 
USA). The current was increased until the doublet stimulus (separated by 10ms) induced a torque 
equivalent to ≥ 25% MVC. 
   The Fatigue test (Fatigability) 
To measure the VL muscle fatigability, the muscle was intermittently electrically stimulated. To 
distinguish peripheral fatigue from central fatigue, muscle fatigue was induced by controlled 
automated 2 minute electrical stimulation, as PES bypasses both the central motivation and the 
neural causes of fatigue, and the contractions thus induced, reflect only the input of local elements 
beyond the motor neuron junction to muscle.  
The test consisted of 30 Hz, 60 stimuli of 1sec duration, separated by 1 sec rest interval [a duty 
cycle of 0.5 = 50% ] for 2 minutes. This intermittent stimulation protocol allowed relaxation and 
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hence metabolic recovery, between contractions. The test was well tolerated; all participants, as 
visually and verbally instructed throughout the test, remained relaxed (i.e. without knee muscle 
voluntary contraction), and completed the protocol. A fatigue index was calculated as the force at 
the end of the test divided by the peak force during the test. 
3.6 Vascular endothelial function (Ultrasound assisted FMD (US-FMD)   
Due to a sudden surge of blood flow (reactive hyperaemia), the resultant increase in shear stress 
induces the endothelium to release NO that in turn mediates a cascade resulting in arterial dilation. 
This FMD % is not only an index of vascular endothelium health, but also an indicator of the 
presence of any underlying circulating or systemic environmental stimulus. Any compromised 
dilation, is apparent in all arteries of smokers (Tinken et al, 2010) 
To measure this functional change an 8-minute US-FMD test was  performed. After taking baseline 
arterial diameter readings using US, a cuff was strapped and inflated to 50 mmHg above resting 
systolic BP to block flow (Harris et al. 2010). The cuff was released 4.5 minutes later, which induces 
a sudden flow mediated dilation. The probe scan recorded increased flow and sudden rapid dilation 
(Diameter in mm) over the next 45- 75 seconds (Pyke, 2010). The two components of vascular shear 
stress are  automatically  assessed  by  the algorithms of  US as the mean shear stress, which is made 
of summated positive antegrade and negative retrograde stress components and related to the  
laminar blood flow  through, and  causing dilation in, the femoral artery. After cuff deflation, a 
continuous scan was taken with 10-s intervals, for 3 minutes to record all changes in diameter 
dilation and return to rest values. 
 
3.7 Statistical analysis  
The muscle and arterial function test data differences between smokers and non-smokers and 
between pre and post smoking cessation were statistically evaluated and compared with SPSS. 
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Multiple regression analysis using repeated measures ANOVA with post hoc Bonferroni’s test was 
used to determine the predictors of functional improvement in luminal diameter change in response 
to 2-week cessation. Between and within groups comparisons were carried out. Signiﬁcance was 
accepted at P < 0.05. Reliability tests were performed in terms of pre (at Day 1 ) - and 2 weeks post 
measurements in non-smoker controls. All measured values were deemed reliable. 
 
3.8 Definitions 
Cessation (SC) was considered successful if cotinine levels were less than 20 ng.mL-1 and COHb 
of 0% at the 2-week time-point. Current Smoker (S) was defined as current smoking on enrolling 
for study or blood level of cotinine >20 ng.mL-1.   
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4. Results 
4.1 Participant characteristics 
There were no significant differences in age, body height, and body mass and body mass index 
between the smokers and non-smokers (Table 1). As expected, none of the other parameters in our 
study changed significantly in the controls (non-smokers) over 2 weeks. This indicates that our 
measurements were reproducible and that any changes detected in smokers are due to smoking 
cessation.  
Table 1. Participants’ Characteristics C: combined pooled mean of control values taken on Day 1 and Day 14. S: Smokers 
values taken before and after smoking cessation (SC). n= number of Participants, m=men, f=women .BMI: Body mass index. 
All values are expressed as mean ± SEM. 
 
4.2 Biomarkers of smoking (Cotinine and COHb) 
 
To verify that smokers abstained from smoking we measured both COHb and cotinine. Both 
cotinine and COHb levels were higher in smokers compared to non-smokers (Fig. 1A, B; P < 
0.0001).  The Cotinine (Fig. 1A) and COHb (Fig. 1B) levels were significantly reduced after 
smoking cessation (P < 0.001). However, as expected, two habitual smokers were not able to 
maintain smoking cessation for the full 2 weeks and were therefore excluded from further analysis 
concerning the effects of smoking cessation. 
 
   
 Figure 1. Blood Cotinine and carboxyhaemoglobin (COHb) levels.  The effect of smoking and smoking 
cessation on - A) Blood Cotinine (ng.mL-1) in smokers before (S1) and after smoking cessation (SC 14).  (B) Blood 
COHb (in %) in smokers before (S1) and after smoking cessation (SC 14). m=men, f=women, n= number of 
participants * = significantly different from control at p, 0.0001 and + = significantly different from S1 at p < 0.001 the 
values are mean ± SEM.   
 
 
Variable 
C 
n=4 
m=3,f=1 
S 
n=8 
m=5,f=3 
SC 
n=6 
m=5,f=1 
Age (yrs.) 24.5 ± 0.9 31.8 ±  3.4 31.8 ±  3.4 
Height (m) 1.79 ± 0.02 1.72 ± 0.03 1.72 ± 0.03 
Body mass (kg) 76.6 ± 4.9 70.1 ± 2.8 70.0 ± 3.5 
BMI kg.m¯² 23.8  ± 1.4 22.6 ± 1.0 22.4  ± 0.9 
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Fig 1  The effect of smoking and smoking cessation on - A) Blood Cotinine (ng.mL-1) and  (B) on blood  carboxyhaemoglobin 
COHb  (% ) in Non-smoking controls (C), and  smokers  (S) before  and after smoking cessation (SC) . * = significantly 
different from control at P < 0.0001 and + = significantly different from S at P < 0.001. The values are means ± SEM. 
4.3 Cardiovascular characteristics  
There were no significant differences in systolic BP, diastolic BP, pulse pressure, stroke volume, 
cardiac output and total peripheral resistance between the smokers and non-smokers (Table 2). 
The resting heart rate was 21 % higher in smokers compared to non-smoking controls (P<0.001) 
and was decreased by 14 % after 14 days smoking cessation (P< 0.002, Fig.2A). 
 
Cardiovascular Function 
C 
n=4 
m=3,f=1 
S 
n=8 
m=5,f=3 
SC 
n=6 
m=5,f=1 
BP-S (mmHg) 128.6 ± 7 134 ±  6 120 ±  6 
BP-D (mmHg) 68 ± 3.4 74 ± 2.7 65 ± 4.2 
PP (mmHg) 60 ± 4.2 60 ± 6.1 55 ± 8.1 
SV (ml) 105  ± 7.3 106 ± 110 97  ± 14.2 
CO (Lmin-1) 6.6  ± 0.7 8.5  ± 0.9 6.5  ± 0.8 
TPR mmHgL-1min-1 .014  ± 0.0 .012  ± 0.0 .013  ± 0.0 
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Table 2.  Cardiovascular functions. C:  mean of controls, S: Smokers values taken before and after smoking cessation (SC). 
n= number of Participants, m=men, f=women .BP-S systolic blood pressure; BP-D diastolic blood pressure; PP-Pulse 
pressure; SV: stroke volume; CO: Cardiac output; TPR : Total peripheral resistance . All values are expressed as mean ± 
SEM. 
 
The mean arterial pressure was higher in smokers than in non-smoking controls (P< 0.001) and 
was decreased after smoking cessation (P< 0.002; Fig.2B). The rate pressure product was higher 
in smokers than in non-smoking controls (P< 0.001) and returned to normal levels after smoking 
cessation (P<0.002; Fig.2C). 
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Figure 2: The effect of smoking and smoking cessation on- (A) Resting Heart rate (beats.min-1)    (B) on Systolic Blood 
pressure (mmHg) (C) on mean arterial pressure (mmHg.)    . (D) On Rate pressure product  (RPP in beats.min-1.mmHg   in 
Non-smoking controls (C), and  smokers  (S) before  and after smoking cessation (SC)  * = significantly different from control 
at P <  0.05 and + = significantly different from S at P  < 0.001. The values are means ± SEM. 
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There were no significant differences in systolic BP, diastolic BP, pulse pressure, stroke volume, 
cardiac output and total peripheral resistance between the smokers and non-smokers (Table 2). The 
resting heart rate was 21 % higher in smokers compared to non-smoking controls (P< 0.001) and 
was decreased by 14 % after 14 days smoking cessation (P< 0.002; Fig.2A).The mean arterial 
pressure was higher in smokers than in non-smoking controls (P< 0.001) and was decreased after 
smoking cessation (P< 0.002; Fig.2B). The rate pressure product was higher in smokers than in 
non-smoking controls (P<0.001) and returned to normal levels after smoking cessation (P<0.002; 
Fig.2C). 
 
 4.4 Muscle functions  
 
Table 3: The effect of smoking and smoking cessation on muscle function. m=men, f=women, n= number of Participants.  
MVC = Maximum Voluntary Contraction; VA = Voluntary Activation;  C: Mean of controls ; S: Smokers ; SC : Smoking  
cessation. The values are expressed as Mean ± SEM.  
 
 
Muscle Function 
C 
n=4 
m=3,f=1 
S 
n=8 
m=5,f=3 
SC 
n=6 
m=5,f=1 
MVC (N) 730 ± 33 655 ±  54 697 ±  61 
VA (%) 92 ± 3.3 89 ± 4.1 89 ± 3.1 
 
  
Muscle strength: (Maximum Voluntary Contraction) 
The MVC torque in smokers was significantly lower than  non-smokers (P< 0.02; Fig 3A). When 
correcting for the lever arm the MVC force tended to be lower in the smokers than non-smokers (P 
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=0.09;Fig.3B).There were no significant difference in voluntary activation and fatigability  scores 
between smokers and non-smokers (Table 3).   
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Fig 3 : The effect of smoking and smoking cessation in smokers before (S) and after smoking cessation (SC)  - A) on Right 
Vastus lateralis Torque (N.m)  (B) on   maximal voluntary contraction (MVC in Newtons)   (C) on Fatigue Index (%)   C: 
non-smoking controls; F I = Fatigue Index; * = significantly different from control at P < 0.01 and + = significantly different 
from S at P < 0.001. The values are mean ± SEM.  
 
   
 
4.5 Femoral artery vasomotor function  
 
 
Table 4  The effect of smoking and cessation on Vascular function  C: pooled mean of values of controls taken on day 1 (D1) 
& day 14 (D14), S : Smokers values on Day 1 before cessation , SC : Smokers scores on Day 14 of cessation, m: men, f :women, 
n:number of Participants, L & R FA (Left & Right Femoral Artery), Pre and post-test vascular function scores of R FA 
artery in Participants before and after muscle function test, D:Diameter,Vel:Velocity, FMD : flow-mediated dilation in L 
FA.The values are expressed as the Mean ± SEM .  
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Vascular Function 
C 
n=4 
m=3,f=1 
S 
n=8 
m=5,f=3 
SC 
n=6 
m=5,f=1 
Pre-test RFA- Vel (cm.s-1) 20 ± 2.0 17.8 ±  0.78 18.9 ±  1.04 
Pre-test RFA- Flow rate 
(ml.min-1) 
516 ± 39.0 436 ± 50.3 409 ± 45.0 
Post-test RFA-D (mm) 7.5 ± 0.29 6.9± 0.24 6.9 ± 0.36 
Post-test RFA Vel (cm. s-1) 24.5  ± 4.4 24.0± 1.6 25.0  ± 1.8 
LFA FMD (%) 10.3  ± 3.2 10.0  ± 2.4 13.3  ± 2.4 
 
 
Diameter  
 
R FA mean pre-test diameter at day 1 was significantly lower (9%) in smokers (S1) than controls 
(C), P=<0.02, Table 4). There was no significant change after 2 week smoking cessation (P=0.06, 
Fig 4 A) function test in smokers was significantly lower (21%) compared with controls (C) (P= < 
0.01, Fig 4 B), the flow rate increased significantly (5 % = 31 ml.min-1) after muscle function test 
in smokers after 2 week cessation compared with controls (C) P= < 0.03, Fig 4B) 
 
Velocity  
  
Rt   F A  blood  velocity before and after  muscle function tests  in smokers, before and after  2 
week smoking cessation  was not significantly different  when  compared with controls (C)  (P= < 
0.09)(Table  4 )  
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The degree of FMD expressed as change in diameter was examined in C, S and SC. A reduction in 
the degrees of vasomotion was evidenced in smokers in comparison with control .After cessation 
of smoking this was increased. (Fig 5 A, B ) 
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r e l e a s e .   *  =  s i g n i f i c a n t l y  d i f f e r e n t  f r o m  c o n t r o l  a t  P  <   0 . 0 0 1  a n d  +  =  s i g n i f i c a n t l y  d i f f e r e n t  f r o m  S  a t  P   <
0 . 0 1 .  T h e  v a l u e s  a r e  m e a n s  ±  S E M .
*
*
*
In summary, the diameter and flow rate changes were observed with short cessation, but were not 
significant. 
Discussion 
The main findings of the present study are that smoking is associated with a reduction in vascular 
function and muscle force generating capacity that cannot be restored within two weeks of smoking 
cessation. 
 
37 
 
5.1 Nicotine and CO (Biomarkers) 
To verify that the smokers were really smoking and had really stopped smoking during the 
smoking cessation study; we measured the COHb and cotinine levels in the blood. The  levels of 
nicotine and CO in the smokers group were higher than controls and normalised after smoking 
cessation (Fig.1A, 1B). 
 
5.2 Muscle function 
 Torque 
 
In line with other studies (Orlander et al. 1979, Al-Obaidi et al. 2004), we found a lower maximal 
voluntary strength (MVC) in smokers. Such a decline can be a consequence of a smaller muscle 
mass, a reduced ability to activate the muscle voluntarily, increased activation of antagonistic 
muscles during a maximal contraction and/or smoking-induced muscle damage. Cellular damage 
by definition is understood as lasting alteration of cellular or subcellular parts that do not respond 
to intervention. A smaller muscle strength could be the consequence of lower levels of activity in 
smokers as observed previously (Orlander et al. 1979). In the present study smokers and non-
smokers were matched for physical activity level and, similarly to Larsson et al. (Larsson 1984), 
we did not observe a difference in strength between smokers and non-smokers. Thus, the decrease 
in strength observed in previous studies is likely to be explicable by a reduced activity level in 
smokers, rather than an effect of smoking per se on maximal knee extensor strength or other 
determinants of strength (activation). Yet, it has been reported that hypoxia can cause damage to 
sarcomeres and sarcolemma and be associated with a delayed recovery (Mayer et al, 2014). Our 
data do suggest, however, that smoking does not induce, at least in the young people we recruited, 
the extensive muscle fibre damage and localised  and persistence necrosis (Lehr.2000; Mayer et 
al,2014) observed by others. Similar to the previous observations (Luu, 2013; Feitelson et al, 2002) 
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muscle torque correlated positively with the resting femoral artery blood flow (Fig 6B). This 
suggests that there is some link between muscle and vascular function. 
 
Fatigue 
COHb also hampers the release of O2 as reﬂected by the leftward shift of the O2-Hb binding curve. 
Furthermore, the facilitated diffusion of O2 by myoglobin within the muscle may be impaired by 
the formation of carboxymyoglobin (Wittenberg & Wittenberg 1987). It has been reported that the 
raised levels of COHb reduce O2 extraction during the stimulated contractions in in-situ canine 
gastrocnemius, which was accompanied by a reduction in muscle tension (King et al. 1987).  
Our study showed 4% hypoxia by an indirect measure of 4 % COHb. However, a reduced O2 
carrying capacity of the blood induced by breathing hypoxic air had no effect on fatigue resistance 
during the same test as employed in the present study (Degens et al. 2006), although others did 
observe an earlier muscle fatigues during hypoxia (Katayama, Amann, Pegelow, Jacques, & 
Dempsey, 2007; Romer et al., 2007). Whatever the cause of the discrepancy, it should be noted, 
however, that the tissue hypoxia might be more severe than expected from the increase in COHb, 
as the oxygen dissociation curve is shifter to the left, resulting in an impaired dissociation of oxygen 
from the Hb molecule.  
In addition, there might be problems with the ability to use oxygen, as reflected by the lower 
mitochondrial enzyme activities (citrate synthase and 3-hydroxyacyl-CoA dehydrogenase) in the 
muscles of smokers than non-smokers and the 23% inhibition of COX (complex IV) activity in 
mitochondria of lymphocytes (Orlander et al. 1979; Alonso et al, 2003).  
Although only two percent of the oxygen will be oxidized to an unstable reactive oxygen species 
(ROS-superoxide) in complex III and a 40-50 minutes of hypoxia increased ROS by 2.5 fold short 
time. The elevated ROS production during hypoxia and derived from cigarette smoke, may cause 
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activation of cell signalling pathways, that result in muscle protein breakdown, damage to muscle 
membranes and oxidised proteins (Degens et al., 2015; Hoppeler, 2003).  
Indeed, in smokers it has been observed that mitochondrial function may be further impaired by 
oxidative peroxidation as observed in ‘outer cell membrane of lymphocytes’ in smokers and 
systemic inflammation (Alonso et al, 2003; Meyer et al, 2013). Such an inflammatory process, at 
the level of muscle myofibrils, may also be interlinked with disturbed glycogen stores and usage, 
and may play a vital role in the muscle energy metabolism, catabolism and efficiency.  
Interestingly, this instability in metabolism was all reversed after as little as 24 hr smoking cessation 
and healthy ex-smokers did not show lower activities of enzymes of oxidative metabolism than non-
smokers (Larsson, 1984). These and the observations in COPD patients who stopped smoking, who 
exhibited improved fatigue resistance, suggests that the smoking-induced deranged alterations in 
the activity of oxidative enzymes and muscle fatigue resistance are reversible (Degens et al., 2005) 
. Such reversible changes may be related to the wash out of cyanide that by polarising the membrane  
decreases the electron flow in complex I and of CO that inhibits cytochrome c oxidase (complex 
IV) (Alonso et al. 2003;Fontaine et al,1999),  These are thought to alleviate some of the potential 
negative effects on muscle fatigue resistance.  
Surprisingly, we did not see overall improved muscle function. Despite all the elevated COHb in 
our study and all the other potential mechanism discussed above we did not observe significant 
differences in muscle fatigue resistance between smokers and non-smokers, or an impact of 
smoking cessation on muscle fatigue resistance, similar to other studies employing voluntary 
contractions (Orlander et al. 1979, Larsson 1984). This is in contrast with our previous studies, 
where we did see a lower muscle fatigue in smokers, which may be due to a decline in contraction-
induced blood flow in the peripheral vessels of the leg (Degens et al, 2015; Wüst et al., 2008).  
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One possibility for this discrepancy might be the larger number of participants in the study by Wüst 
et al., (2008) than in the present study, as suggested by the similar pattern of differences in fatigue 
resistance in our study. Another explanation could be that the low level of COHb as 6% COHb that 
is often observed in the smokers did result in a reduced muscle fatigue resistance (Morse et al., 
2008). Such an assumption may be misleading. In contrast , some recent evidence suggests that 
even low level chronic CO acts as a vasodilator and increased coronary artery flow rate via 
membrane hyperpolarization by using the antioxidant stress Heme-Oxygenase -I / Carbon 
monoxide (HO-1/CO) pathway  (Slebos, 2003). In addition, the acute neural stimulation effects of 
nicotine in cigarette smoke is well-established (Cryer et al. 1976). Mundel & Jones (2006) have 
demonstrated that nicotine has a beneﬁcial effect on cycling endurance in muscle. In our study, it 
might thus be that the circulating nicotine more than compensated for the detrimental effects of 
COHb on muscle fatigability in our subjects.  
It has been shown that the using of direct muscle stimulation, superimposed on nerve stimulation, 
has shown to cause neurotransmission failure that contributed to an earlier onset of fatigue during 
hypoxia (Zhu et al. 2006). Here we observed no such problem as the voluntary activation did not 
differ significantly between smokers and non-smokers, in line with our previous observations (Wüst 
et al., 2008). 
 
Cardiovascular adaptations 
Our study noted functional improvement in resting HR, MAP and RPP similar to those observed in 
long-term smoking-cessation studies involving six weeks and even 3 years of cessation (Asano, 
2012; Bassareo, 2014).  In another study, the damaging CVD effects were shown to have rapidly 
reversed on smoking cessation (Xu et al., 2013). In asthmatics, smoking cessation induced 
considerable improvement in lung function, decline in the airway inflammation and cutaneous 
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vasoconstrictor responses (Chaudhuri et al., 2006). This suggests that cessation has a beneficial 
effect on heart and lung function and reduces death rate in 10 weeks of cessation (Anthonisen et al, 
2005). We used 2-week cessation only in our study.  
 
Rationale for using two weeks of cessation  
In previous cessation studies, 24 hours of cessation caused a rapid reversal of  endothelial 
dysfunction and 2 weeks cessation had corrected platelet aggregability in high risk patients 
(Hirohiko Morita, Hisao Ikeda and Hiroyuki Eguchi, 2005). Four  weeks of cessation had improved 
myocardial blood flow and coronary endothelial dysfunction in smokers (Morita et al., 2006) and 1 
week cessation had a profound effect on the CV parameters and catecholamines (Minami et al., 
1999). It is not known if two-week cessation would bring improved blood flow in CFA and improve 
fatigability in in Vastus lateralis muscle in smokers. 
 
Changes in vascular function 
Our 2-week cessation results complement and extend from other similar studies of smoking 
cessation involving one day and one-week duration that have also showed significant improvement 
in endothelial function (Moreno et al, 1998; Morita et al; 2006). While we observed benefits of 
smoking cessation on the femoral artery function, the benefits might be even more pronounced in 
the microcirculation. As it has been observed that vascular, changes first occur at the 
microcirculatory level (Saito, 2012; Lehr, 2000; Hosokawa, 2008). 
Nicotine is unpredictable and can lead to both vasodilation or vasoconstriction depending on 
concentration and tissue site (Lehr,2000; Mundel and Jones, 2006).  The normalisation of the resting 
femoral artery diameter after cessation may thus be due to a normalisation of the nicotine levels in 
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the blood. Circulating vasoactive constrictors and inflammatory agents in blood also decrease 
correspondingly on short-term cessation, additionally improving the local blood flow and 
distribution. Briefly, the distinct properties of the endothelium, such as tone, thickness, diameter, 
which are closely linked to the perfusion of muscle tissue are clearly impaired by smoking and can 
be potentially altered by a short or long-term abstinence.  
 
General discussion/mechanisms 
The majority of skeletal muscle  and all  advanced  peripheral, coronary and  endothelial 
dysfunction, that inhibited vasodilation,    observed during  smoking  maybe due to the effects blood 
levels  of substances present  in the inhaled smoke that affect organelles directly 
(Lekakis,1998;Morita,2006;Naya,2011) and/or caused the  disruption of cell signalling pathways 
(Degens et al,2015). For instance, a systemic review of 6-12 months random control trials showed 
that the CO, nicotine and hypoxia during smoking had caused disruption of the vital tubulin 
cytoskeleton that keeps cell functional and stable, in addition to increased   blood platelet 
aggregation (Ludvig, 2005).  
 
5.3 Vascular function  
Diameter  
 
While the arterial diameter (in vasodilation) reflects endothelial wellbeing and its decrease size in 
smoking and its persistence even after 2 week cessation had reflected ongoing dysfunction in  
arterial vasomotion. Many studies have shown that the conduit common femoral artery in healthy 
people does not dilate in response to passive leg movement or in exercise (Trinity, 2012). We 
observed that in smokers, a significant decrease in diameter (30%) had occurred as a result of 
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habitual smoking and a failure to dilate immediately after 2 week cessation and after muscle 
function test was evidently seen.  Such observations confirm persistence of endothelial dysfunction, 
failure of adequate relaxation in large artery even after short cessation. In line with other studies, it 
confirms that it is not the larger vessels but the microcirculation and subcellular regions of muscle 
that are focal points of  responsive action, that experience earliest damage and during smoke 
exposure and also they are the ones that first  to revert to normalcy  in abstinence (Clark et al, 2003; 
Mayer et al, 2014). 
 
Cardiovascular function  
In our study raised RHR, SBP, MAP and RPP- the main central hemodynamic parameters were 
stabilised by short cessation. This rise in systolic BP overtime in smokers had reflected the 
progression of arterial wall pathological stiffness against flow, usually seen in atherosclerosis of 
smokers, as ED had progressed over duration of habitual smoking (Langham et al., 2015). While 
diastolic BP reflects coronary flow reserve and the perfusion of the myocardium. Heart rate 
increase, which was reflection of the pumping action of overstressed heart in smokers, was 
significantly reduced on cessation. As  the resting heart rate changes are linked with lifestyle habits 
and independently predict cardio metabolic risk and mortality lowering it would cut these risk 
immensely (Palatini et al., 1999; Palatini, 2013). Raised systolic BP, predicts CVD risk and has two 
main components; pulse pressure (PP) and mean arterial pressure (MAP). PP is the pulsatile 
component of the BP, which is directly affected by LVEF and  associated with MI, carotid stenosis 
and CVD death. The MAP is the steady component of blood flow through the aorta and its branches. 
It reflects the vital functions of LV contractility, heart rate and vascular resistance that is averaged 
over time. According to a  study, a 10 mmHg rise in  MAP above normal range ,strongly correlated  
with  12% rise in  relative risk of CVD  risk being (1.48)  in the young smokers less than 60 years 
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of age  (Sesso, 2000). On cessation, a similar reduction in MAP in our study, suggestively reflects 
a strong resurgence of overall recovery in cardiovascular function, and an onset of  possible vascular 
remodelling, that mirrors the initiation of clinical advantage in this young cessation cohort. 
Additionally, the lack of increase in PP suggests that the peripheral conduit artery, the femoral artery 
in our case, did not progress at least to stiffening, but was associated with lowered systemic vascular 
load and some increased coronary perfusion (Sesso,2000). These adaptations alone offer a great 
clinical advantage to smokers and this knowledge of rapid physiological recovery may be an 
incentive for smokers to adopt a long-term cessation or to choose quitting permanently  
 
Blood velocity, the flow and the CFA 2 diameter dilation observed in cessation were not improved 
by 2-week cessation significantly, even as the endothelial functions remained inhibited. However, 
the blood flow function may be enhanced in cessation and on passive exercise of large muscles. 
Some studies show this. A study of an isolated passive muscle  extension exercises of quadriceps , 
with NOS  inhibition, had caused  reduction in  hyperaemic blood flow  and vasodilation responses  
(by 80 % ) in comparison to controls  and these effects were independent of the relative exercise 
intensity (Trinity et al,2012).  Suggesting that passive exercise had improved hyperaemic (flow) 
that  had increased nitric oxide synthase (NOS) activation via the  endothelial NG-monomethyl-L-
arginine (L-NMMA).pathway and facilitated the bioavailability   of arterial NO, such that NO alone  
had contributed to the   amount of vasodilation and flow (Trinity et al, 2012). Applying this principle  
to our outcome This  clearly indicates that   our  short smoking cessation had not improved the flow 
mediated NO release nor its availability ,nor had influenced the cellular pathway to any 
improvement  in our smokers, as the baseline endothelial NOS inhibition dysfunctions had persisted 
and had not improved significantly as to see a change. There may be several possible explanations 
as to why no change had occurred in vessels and muscles as measured by us after 2 weeks of 
cessation. 
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5.4 Smoking cessation 
It is known that smoking cessation improves the cellular and systemic environment as its antioxidant 
system washes out toxins from the body, leading to an adequate recovery. Above we have reported 
this as the restoration process of mitochondrial function seen in lymphocytes after 24 hours of 
smoking cessation. This is, however, may not the only effect of smoking cessation, as it is likely   
to boost antioxidants. It is also reported that DNA damages and arterial plaques were repaired 
because of smoking cessation, which would translate into clinical benefits such as vessel wall 
remodelling (Ishida, 2014; Lane, 1997; Lietz, 2013). The question however is, how long should this 
cessation be in order to realise these effects in smokers? 
 
Duration of cessation  
Although temporary cessation in smokers clearly mitigates some problems of smoking, but Lee et 
al (2013) has advocated a longer cessation for more specific muscle function benefits. Several 
animal and human studies have suggested that in order to see a verifiably significant reversal in 
muscle functions, the smoking cessation, in an oxygen rich environment, must at least be   equal to, 
the time and duration of smoking exposure (Yen et al, 2008; Caron et al, 2013). In our study, most 
of the smokers were chronic smokers with a 3- to 10-year smoking history and our two-week 
cessation may thus have been inadequate to see substantial improvements in the muscle function. 
Studies with longer duration of cessation explain some facts lacking in our study.  Interestingly a 
study of six weeks of cessation, in asthmatics, had induced a considerable lung function 
improvement, coupled with a decline in the airway inflammation and a gross improvement in the 
cutaneous vasoconstrictor response (Chaudhuri et al., 2006). In another long cessation study, the 
damaging CV and ED effects were reversed only after 3 and 7 years long smoking cessation (Xu et 
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al., 2013; Hosokawa, 2008). These long cessation-induced function reversals studies were also 
associated with a reduced disease risk (Xu et al., 2013).  
It has been observed that the magnitude of the vascular function response was related to the duration 
of cessation. Other studies  have noted, however, that the duration with as little as 12 weeks of 
lifestyle intervention,  including smoking cessation was insufficient to induce an increase in the 
resting arterial diameter and advocated a period of 6 months of cessation to see a complete arterial 
reversal (Spence et al., 2013; Bassareo et al., 2014). Some investigators suggest that a part of the 
discrepancy may be related to a different response times in different arteries (Spence et al., 2013). 
Our study shows, however, an encouraging data as we already saw a positive normalisation trend 
of vascular function and gain of some muscle strength after just 2 weeks smoking cessation. It is 
thus questionable, whether such long duration of smoking cessation is actually required. 
Aids to smoking cessation  
 
Although Nicotine Patches have a low dose of nicotine with some additional chemicals, from a 
public health perspective, it is still the first line to support for cessation, as it does not contain those  
4000 active particles, chemicals and tar-like substances present in the mainstream cigarette smoke 
(Rom et al., 2013) NRT is helpful up to some extent in smokers . However, in the interest of safety, 
and possible CV endothelial dysfunction effects, clinicians are cautious to co-prescribe Nicotine 
patches with substances like Bupropion, as they are still chemical medications that may cross-react 
with prescribed drugs (Benowitz, 2013). Indeed, a study that investigated NRT as a cessation 
modality, conclusively discouraged its use, as is was reported unsafe and risky as it had worsened 
endocrine glucose metabolism and fatigue symptoms were precipitated and was associated with 
weight gain (Tonstad, 2009). 
Two of our participants used nicotine patches or gum briefly, to keep the intense craving away 
especially at the onset of the second week of cessation. They were advised to use some Lemon juice 
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(Vit C- an anti-oxidant) instead, to keep the craving away. The details of gum use, duration and 
strength was not recorded, as it did not seem to help them. The transient usage of gum or patch did 
not possibly cause some physiological changes to a great degree but it appealed more so on 
psychology of these two participants, as they seem to feel well. It possible that nicotine may have 
helped these users in some way if they used it consistently and frequently in higher doses (2 mg).  
However, we know that Nicotine can also increase muscle endurance shown in other studies.  
Nicotine infusion was found to be vasodilatory (Benowitz, 2013) and we may thus have 
underestimated the impact of smoking on vascular function.  
 
5.5 Implications  
Among the 4000 substances present in the cigarette smoke, many may specifically have a 
detrimental effect on muscle fibre structure and function (Rom et al, 2013). Our knowledge of how 
smoking affects muscle and vascular function is limited and to what extent cessation reverses the 
detrimental effects of smoking is growing. However, the exact molecular mechanisms in effective 
fatigue reversal has remained elusive. vascular dysfunction - Impairment or damage? 
Our study assumed that the vascular dysfunction in chronic smokers was an impairment. By 
definition, functional “impairment” is a temporary and reversible phenomenon while damage is 
lasting and not easily irreversible in a short time.  Although we believe endothelial dysfunction in 
smokers is primarily a reflection of oxidant damage, they would potentially improve with long 
cessation and antioxidant support.  
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SCHEMATIC 
 
5.4 Limitations of the study 
Although our study, of small sample size, was focussed primarily on nicotine and CO associated 
muscle dysfunction, other particulate anions and aldehydes could also have contributed to the 
persistence of muscle and vessel dysfunction. Further research is warranted to assess their role in 
the muscle and vascular function in smokers. As it is known that the smoking cessation studies in 
humans, by nature are challenging because they involve strict abstinence in habitual smokers, and 
due to the intense craving choose to drop out of the cessation study. If when conducting such a 
study, in study, in a larger sample, in residential rehabilitation lifestyle centres, with a longer period 
of abstinence, it would provide more comprehensive data on the effects of, the long-term smoking 
and smoking cessation on vascular and muscular function. Our study, like most fatigue study 
protocols, did not consider the contributions of synergistic and antagonistic muscles in the 
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determination of muscle fatigue resistance. This is unlikely a minor problem, however, as we used 
electrically evoked contractions bypassing the central nervous system. 
 5.6 Conclusions 
The findings of our study suggest that long-term smoking bears serious deleterious effects on both 
the vascular endothelium and force generating capacity of the VL. It was encouraging to see that 
despite the small sample size, there were significant normalisations of resting femoral artery 
diameter, resting heart rate, mean arterial pressure and rate pressure product; all these significantly 
indicating that a 2-week smoking cessation resulted in a rapid initiation of reduced strain on the 
heart and Cardiovascular system. 
--------------------- 
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7. Appendix  
 
1. Structure and function of muscle and blood vessel. 
1.1 -Structural and Functional organisation of muscle In the human body are 600 muscles arranged in pairs 
or groups that together comprise approximately 40% of the body mass. Almost all muscles attach to 
bones, and on receiving an electrical stimulus or action potential, they contract and initiate movement. 
A single muscle cell, also known as a muscle fibre, is a multi-nucleated cell, made up of myofibrils. These 
are arranged in contracting units called sarcomeres. The sarcomere is the smallest functional unit of 
myofibrils made of the contractile proteins actin and myosin. The light-dark banded sarcomere, 
measuring 2-2.5 microns (from Z to Z line), is made of parallel contractile and stabilising structural 
proteins (M line proteins, titin, nebulin, α-actinin, desmin, Spectrin, dystrophin). The alternate bands, 
light (I) band and central dark (A) band of the sarcomere, are evident, when seen through the Electron 
microscope. The A band is constant in width and contains the myosin and remains constant in length 
during contraction. The I band contains actin, but no myosin, and changes its length during contraction. 
The Central H zone is where actin and myosin overlap. Titin molecules connect both ends of Myosin to 
the Z line (Fig. 1; Jones and Round, 1990) 
1.2 Actin Actin is a filament made of G-actin monomers and has a molecular weight of 42,000 Da. Each actin 
filament consists of two beaded protein strands twisted together and has points of attachments for 
myosin heads, the myosin binding sites. Each actin is surrounded by 3 myosins, which can interact with 
the actin filament. In the groove of the actin helix lays tropomyosin that in the resting state covers the 
myosin binding sites on the myosin molecule. Tropomyosin is associated with three troponin molecules 
(TnC (Ca+-sensitive), TnT and TnI). When Ca2+ released from the sarcoplasmic reticulum in response to 
depolarisation of the plasma membrane binds to the TnC subunit, it moves the tropomyosin protein to 
uncover the underlying binding sites for myosin heads to attach and the cross bridge cycle starts.  
Myosin  
Each myosin molecule (molecular weight of 200,000 Da) consists of a tail and two opposite head (S1) regions. 
In between the head and the tail is a flexible neck region (S2). In the centre, the orientation of the head 
changes in the opposite direction. The head has the binding site for actin to form a cross bridge, and the site 
to hydrolyse ATP.  
Cross-bridge cycling 
Actin [thin filaments] and Myosin [thick filaments] are arranged in parallel to each other. The sliding 
interaction between them, by cross-bridge formation, is responsible for muscle contraction. The sliding 
filament theory of muscle contraction states that the 2 sets of actin filaments, anchored on to the opposite 
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Z lines, are pulled inwards towards the centre of the sarcomere, by the myosin filaments. As a result, the 
sarcomere is shortened along with the I band.  For this to happen, the myosin heads, energised by binding 
ATP, attach to the nearby actin filaments and form connecting cross bridges.  The cross bridge attachments 
and hydrolysis of ATP lead to the initiation of power stroke that creates shortening, and a generation of force 
in the sarcomere. This cyclical process is followed by binding of ATP to the myosin head, causing detachment, 
and making the myosin ready for the next stroke of contraction. This cumulative generated force by a large 
number of cross-bridges in fibres is used for body movement tasks. 1.2 Muscle contraction function When 
an action potential arrives at the neuromuscular junction it is transmitted to the t-tubuli, resulting in the 
release of Ca2+ from the SR. This Ca2+ then binds to TnC which in turn causes a conformational change in 
tropomyosin unblocking the myosin binding sites on actin. The hydrolysis of ATP results in cross bridge and 
the subsequent power stroke. The inward pull on the bilateral actin filaments by the myosin heads, results 
in shortening and force generation. This coupling between electrical excitation and subsequent contraction 
is called excitation–contraction coupling (Shorten,  et al , 2007).  
There are 2 types of contractions; Isometric and Isotonic; during an isometric contraction the muscle length 
remains constant, while during an isotonic muscle contraction the tone remains constant.1.3 Vascular 
structure and function   Vascular endothelium. The innermost lining is the vascular endothelium, which is 
present in the arteries, veins and capillaries. In terms of its surface area it is the largest organ in the body, 
with a surface area equivalent to that of 10 football fields! The vascular endothelium is composed of 
endothelial cells that serve as a permeable barrier between the surrounding tissue (including vascular tissue 
in larger blood vessels) and the blood. In arteries, we have from the inside of the vessel to the outside first 
the endothelium, then the tunica intima, then the tunica media, consisting of vascular smooth muscle cells, 
and then the tunica adventitia, consisting of fibrous coating, houses nerves and blood vessels. The vascular 
endothelium is critical for the adequate functioning of the cardiovascular system. It regulates vascular tone, 
the selective transport of substances into the cells, as well as platelet aggregation, coagulation and 
fibrinolysis (Wheatcraft et al, 2003). 
1. Endothelium in health Normally, endothelium-induced relaxation of smooth muscle cells in the arteries 
and arterioles expands the lumen in arteries; vasodilation. Acetylcholine induces decreased vasomotor 
tone in arteries caused by the release by the healthy endothelium of nitric oxide, which spreads to the 
underlying smooth muscle cells and excites calcium efflux by a cyclic guanosine monophosphate-
dependent pathway, resulting in smooth muscle relaxation. (Mays, 1998).The increased arterial 
diameter results in an increase in flow, improving tissue perfusion, increasing oxygen delivery, and 
thereby the removal of toxic waste products and heat. It is therefore no surprise that during increased 
contractile activity, muscle blood flow is elevated, and paralleled by a rise in VO2 (Richards et al, 2012). 
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In addition, one can expect a reduced muscle fatigue resistance in the presence of an impaired ability to 
elevate blood flow during contractile activity.   
1.4. Arterial Function The blood vessel regulates myogenic flow by constricting and dilating in response to a 
series of vasoactive molecules derived from the endothelium. The most important vasodilators are nitric 
oxide (NO), prostacyclin and endothelium-derived hyperpolarising factor (EDHF). On the other hand, 
angiotensin II, endothelin-I and thromboxane A2 are amongst the main vasoconstrictors. An intricate 
homeostatic balance between the secretion of the vasodilators and vasoconstrictors achieves the 
vascular tone. The simultaneous constriction of some vessels and dilation of others allows for the 
redistribution of blood to different tissues during feeding, exercise and maintenance of body heat 
(Barton, 2011). Endogenous release and use of  NO also has a dominant role in vascular health and blood 
homeostasis because of its antiplatelet, antithrombotic and anti-inflammatory properties (Ludvig, 2005). 
A major functional role of NO is vasorelaxation that results in increased diameter of blood vessels and 
increasing blood flow. 
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2.. .Poster advert  
Want to quit smoking?
Do you smoke and often feel tired?
Research at MMU has shown  that smokers experience a 
higher level of muscle fatigue than non-smokers, which 
maybe due to impaired vascular function. In a follow-up 
study, we will investigate whether these effects are 
reversible by smoking cessation. So, if you intend to quit 
smoking (for at least two weeks) we invite you to 
participate in our study to follow the improvement in 
fatigue resistance of your leg muscle and vascular 
function.
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3...Data sheet  
Smoking study 201314 
  MMU HSD 
  
 
4. Descriptive Informed Consent form 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Appendix IV 
 
 Informed Consent Form (to be retained by the investigator)  
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Participant:   
 
Name:    Sex: Male / Female 
 
Date of Birth:        
       
Supervisors/Principal Investigator:  Dr. Hans Degens; Dr May Azzawi , Miguel Diaz,/ Sujay Chavan 
 
Investigator/Collaborators:  
 
Ethics Committee Approval Number: 
 
Project Title: Impact of smoking /cessation  on muscular and vascular function  
 
Purpose of study and brief description of procedures.  
 
In previous studies we have found that fatigue is more pronounced in the skeletal muscle of smokers than that 
of non-smokers. The altered state of fatigue in  muscles  is  possibly due to altered structure in blood vessel wall 
due to acute toxic load (Nicotine) in blood ,  leading to decreased blood supply  and  reduced ability of the 
surrounding tissue  to take up  oxygen for energy generation. The aim of the experiments is to explain whether 
changes in blood vessel mechanism   do occur and cause decreased flow in muscle tissue of young healthy 
smokers of varied duration of smoke exposure (toxic load) . To prevent any bias related to the acute effects of 
cigarette smoke, you should refrain from smoking for at least 2 hours before each visit of the laboratory. 
 
The study will be conducted in two parts, the first part of this study will consist of an assessment of 
Nicotine toxic load  in blood  at baseline ie 2 hours of abstinence .A 3 ml sample of blood will be drawn 
to know the toxic level. In the smokers group , the next step will be to allow them to smoke 1 cigarette 
in < 5 minutes and blood will be drawn and ultrasound scans  of the blood vessel will be carried to 
check the immediate  effect of toxic load on the vessels’ tone . Some people may perceive the blood 
drawing as uncomfortable. However, the small stinging is only  a small once with cannula is fixed on 
. In case you cannot stand you  have the possibility to prevent any further action or withdraw from the 
study. Muscle study to see effect on strength of contraction and fatigue time During a second session 
at least 2 weeks of smoking cessation .after the first one, the  blood test  and ,scan   test will be repeated 
same way.  The US scan test of vessel  is much less discomforting (gel may feel sticky and cold)  than 
in the blood drawing. All the stinging  sensations disappear within 20-30s after release of the cannula  
and there are no long-lasting after effects.  
 
As stated above, you are required to refrain from smoking at least for 2 hrs before each laboratory visit and two 
weeks after first test . We request that you keep a record of your smoking behaviour throughout the study and 
jot down any failure ( so we could record it) 
 
We will support any effort to quit smoking. 
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Participant Statement 
 
I fully understand what is involved in taking part in this study. Any questions I have about the study, or my 
participation in it, have been answered to my satisfaction. I understand that I do not have to take part and that I 
may decide to withdraw from the study at any point without prejudice. I have had my attention drawn to the 
document 'Ethical Regulations for the Use of Humans in Research'. My concerns regarding this study have 
been answered and such further concerns as I have during the time of the study will be responded to. It has 
been made clear to me that, should I feel that these Regulations are being infringed or that my interests are 
otherwise being ignored, neglected or denied, I should inform the Chair of the Ethics Committee of the 
Department of Exercise and Sport Science, Manchester Metropolitan University, Hassall Road, Alsager, 
Cheshire, ST7 2HL who will undertake to investigate my complaint. 
 
 
Signed .................................... Date ............................. 
 
I certify that the details of this study have been fully explained and  
described in writing to ................................. and have been  
understood by him/her and that I consent to his/her participation in this study. 
 
 
Signed ....................................................... Date .......... 
(Parental consent for minors only) 
 
 
5. Equations OF muscle function AND NORMAL; VALUES  
 
MVC (force) = (N) 
MVC (torque) = MVC x Lever (N.m) 
 
FI  ratio = F1 /F2  
6. .Equations OF CV FUNCTION  
  
Primary measured haemodynamic (Normal values) data 
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Arterial blood pressure (BP) systolic (SP) = 90 - 140 mmHg  
  
Diastolic (DP) = 60 - 90 mmHg  
  
Mean arterial pressure (MAP): = 70 - 105 mmHg  
   
Cardiac output (CO): HR x SV/1000 = 4.0 - 8.0 L/min  
 ; where  is the pulse pressure,   
 
Derived haemodynamic data 
 
Cardiac index (CI): CO/BSA  = 2.5 - 4.0 L/min/m2  
  
Stroke volume (SV): CO/HR x 1000 = 60 - 100 ml/beat  
 
Systemic vascular resistance (SVR):  80 x (MAP - RAP)/CO = 1000 - 1500 dyne s/cm5  
 
SVR: Systemic vascular resistance. Represents the load applied to the left ventricular muscle during 
ejection. 
  
RPP Rate pressure product: to measure the workload—or oxygen demand—of the heart, and reflects 
hemodynamic stress. RPP = max HR X max SBP  
 
-------------------------------------- 
 
